<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">30996158</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1349-7235</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>15</Issue><PubDate><Year>2019</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Internal medicine (Tokyo, Japan)</Title><ISOAbbreviation>Intern Med</ISOAbbreviation></Journal><ArticleTitle>Long-term Effects of Androgen Deprivation in a Patient with Spinal and Bulbar Muscular Atrophy - A Case Report with 14 Years of Follow-up.</ArticleTitle><Pagination><StartPage>2231</StartPage><EndPage>2234</EndPage><MedlinePgn>2231-2234</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2169/internalmedicine.1592-18</ELocationID><Abstract><AbstractText>Spinal and bulbar muscular atrophy (SBMA) is a progressive hereditary neuromuscular disease caused by the testosterone-dependent accumulation of pathogenic polyglutamine-expanded androgen receptor protein. A 41-year-old man with SBMA received the androgen deprivation agent leuprorelin acetate for 7 years in clinical trials and underwent castration following the trial. Suppression of testosterone levels for 14 years resulted in a slower disease progression, as measured prospectively with quantitative measurements, than the historical control data reported in previous studies. This suggests that long-term androgen deprivation delays disease progression in SBMA.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hijikata</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashizume</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Shinichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banno</LastName><ForeName>Haruhiko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Keisuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Innovation Center for Clinical Research, National Center for Geriatrics and Gerontology, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobue</LastName><ForeName>Gen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Research Division of Dementia and Neurodegenerative Disease, Nagoya University Graduate School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsuno</LastName><ForeName>Masahisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Intern Med</MedlineTA><NlmUniqueID>9204241</NlmUniqueID><ISSNLinking>0918-2918</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000726">Androgen Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>EFY6W0M8TG</RegistryNumber><NameOfSubstance UI="D016729">Leuprolide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000726" MajorTopicYN="N">Androgen Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016729" MajorTopicYN="N">Leuprolide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009919" MajorTopicYN="N">Orchiectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">androgen deprivation</Keyword><Keyword MajorTopicYN="N">disease modifying therapies</Keyword><Keyword MajorTopicYN="N">leuprorelin acetate</Keyword><Keyword MajorTopicYN="N">spinal and bulbar muscular atrophy</Keyword></KeywordList><CoiStatement><b>Author's disclosure of potential Conflicts of Interest (COI).</b> Gen Sobue: Research funding, Takeda Pharmaceutical; Patent royalties/licensing fees, Takeda Pharmaceutical. Masahisa Katsuno: Fees for promotional materials, Takeda Pharmaceutical; Research funding, Takeda Pharmaceutical; Patent royalties/licensing fees, Takeda Pharmaceutical.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30996158</ArticleId><ArticleId IdType="pmc">PMC6709315</ArticleId><ArticleId IdType="doi">10.2169/internalmedicine.1592-18</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 18: 671-680, 1968.</Citation><ArticleIdList><ArticleId IdType="pubmed">4233749</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobue G, Hashizume Y, Mukai E, Hirayama M, Mitsuma T, Takahashi A. X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 112: 209-232, 1989.</Citation><ArticleIdList><ArticleId IdType="pubmed">2917278</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischbeck KH. Kennedy disease. J Inherit Metab Dis 20: 152-158, 1997.</Citation><ArticleIdList><ArticleId IdType="pubmed">9211187</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352: 77-79, 1991.</Citation><ArticleIdList><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Tanaka F, Adachi H, et al. . Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). Prog Neurobiol 99: 246-256, 2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">22609045</ArticleId></ArticleIdList></Reference><Reference><Citation>Banno H, Katsuno M, Suzuki K, et al. . Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol 65: 140-150, 2009.</Citation><ArticleIdList><ArticleId IdType="pubmed">19259967</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Banno H, Suzuki K, et al. ; Japan SBMA Interventional Trial for TAP-144-SR (JASMITT) study group. . Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 9: 875-884, 2010.</Citation><ArticleIdList><ArticleId IdType="pubmed">20691641</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Suzuki K, et al. . Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy: natural history-controlled study. J Neurol Neurosurg Psychiatry 88: 1026-1032, 2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">28780536</ArticleId></ArticleIdList></Reference><Reference><Citation>Trottier Y, Lutz Y, Stevanin G, et al. . Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 378: 403-406, 1995.</Citation><ArticleIdList><ArticleId IdType="pubmed">7477379</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Sluis TM, Bui HN, Meuleman EJ, et al. . Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. J Urol 187: 1601-1606, 2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">22425112</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Banno H, et al. . Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy. Brain 135: 2838-2848, 2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">22773541</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Suzuki K, et al. . A functional scale for spinal and bulbar muscular atrophy: cross-sectional and longitudinal study. Neuromuscul Disord 25: 554-562, 2015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5608513</ArticleId><ArticleId IdType="pubmed">25913211</ArticleId></ArticleIdList></Reference><Reference><Citation>Sethi R, Sanfilippo N. Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer. Clin Interv Aging 4: 259-267, 2009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2697591</ArticleId><ArticleId IdType="pubmed">19554097</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352: 154-164, 2005.</Citation><ArticleIdList><ArticleId IdType="pubmed">15647578</ArticleId></ArticleIdList></Reference><Reference><Citation>Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 181: 1998-2006, 2009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900631</ArticleId><ArticleId IdType="pubmed">19286225</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hemelrijck M, Garmo H, Holmberg L, et al. . Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol 28: 3448-3456, 2010.</Citation><ArticleIdList><ArticleId IdType="pubmed">20567006</ArticleId></ArticleIdList></Reference><Reference><Citation>Hershman DL, Unger JM, Wright JD, et al. . Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol 2: 453-461, 2016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4852142</ArticleId><ArticleId IdType="pubmed">26720308</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrieu S, Coley N, Lovestone S, Aisen PS, Vellas B. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. Lancet Neurol 14: 926-944, 2015.</Citation><ArticleIdList><ArticleId IdType="pubmed">26213339</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>